文献速递生殖医学

基于血清抗苗勒管激素水平筛选的不育男性中地舒单抗对精液质量的影响:一项随机对照试验

Effect of denosumab on semen quality in infertile men selected by serum level of antimüllerian hormone: a randomized controlled trial.
PubMed 文献 · Fertil Steril · 2025-05-20

这项双盲、安慰剂对照、单中心随机临床试验纳入血清抗苗勒管激素(AMH)≥38 pmol/L的不育男性,按1:1随机接受单次皮下注射地舒单抗60 mg或安慰剂治疗80天,主要结局为精子浓度。中期分析后试验终止(n=179),第80天地舒单抗组与安慰剂组精子浓度差异为-1.0百万/mL(95%CI -2.7, 1.1),无差异;仅在一亚组中观察到探索性增加。

要点

  • 地舒单抗60 mg单次皮下注射未改善AMH≥38 pmol/L不育男性的精子浓度。
  • 第80天精子浓度组间差异为-1.0百万/mL(95%CI -2.7, 1.1),无统计学显著差异。
  • 睾丸体积≤16 mL且无隐睾史亚组中地舒单抗组精子浓度增加29%,属探索性发现。

核心结论

  • 地舒单抗未能改善基于血清AMH浓度筛选的不育男性的精液质量。
  • 地舒单抗在亚组中的正面效应只能视为探索性,需在进一步的前瞻性研究中验证。

研究设计与样本

  • 双盲、安慰剂对照、单中心、随机临床试验。
  • 计划纳入282例不育男性,计划在纳入170例后进行中期分析。
  • 中期分析后试验终止,实际纳入179例,地舒单抗组90例、安慰剂组89例。
  • 干预为按1:1随机接受单次皮下注射地舒单抗60 mg或安慰剂,治疗80天。
  • 主要结局指标为精子浓度。

主要发现

  • 第80天地舒单抗组与安慰剂组精子浓度差异为-1.0百万/mL(95%CI -2.7, 1.1)。
  • 两组间前向运动、总运动或形态正常精子的百分比均无差异。
  • 交互分析识别出睾丸体积≤16 mL且无隐睾史亚组,地舒单抗治疗后精子浓度增加29%(基线8.5百万/mL升至第80天11.0百万/mL)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 试验在中期分析后终止(n=179),未达到计划样本量282例。
  • 亚组阳性效应仅属探索性,需在进一步的前瞻性研究中验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To determine whether denosumab could improve sperm concentration in infertile men selected by serum antimüllerian hormone (AMH) ≥ 38 pmol/L. Mouse models, human testicular tissue models, and clinical intervention studies have suggested that the RANKL-inhibitor denosumab, normally used to treat osteoporosis, can improve semen quality in a sub-population of infertile men. DESIGN: A double-blinded, placebo-controlled, single-center, randomized clinical trial. SUBJECTS: The study was designed to include 282 infertile men with a planned interim analysis after inclusion of 170 men. INTERVENTION: The groups were randomized 1:1 to receive either a single subcutaneous injection of denosumab 60 mg or a placebo treatment for 80 days. MAIN OUTCOME MEASURE: Sperm concentration. RESULTS: The trial was terminated after the interim analysis (n = 179), with 90 men assigned to denosumab treatment and 89 men to placebo treatment. No difference in sperm concentration was found at day 80 between denosumab and placebo-treated men (difference of -1.0 million/mL [95% CI -2.7, 1.1]). Moreover, no differences in percentages of motile, progressively motile, or morphologically normal spermatozoa were found. An interaction analysis identified a subgroup of men with testis size ≤16 mL and no history of cryptorchidism who had an increase in sperm concentration of 29% (8.5 million/mL at baseline to 11.0 million/mL at day 80) after treatment with denosumab. CONCLUSIONS: Denosumab did not improve semen quality in infertile men selected on the basis of their serum AMH concentrations. The positive effect of denosumab in a subgroup can only be considered exploratory and needs verification in additional prospective studies. TRIAL ID: ClinicalTrials.gov: NCT05212337. EudraCT 2021-003451-42.

来源:Fertil Steril,查看原文。版权归原作者所有。

引用

  1. Yahyavi SK, Holt R, Jorsal MJ, et al. Effect of denosumab on semen quality in infertile men selected by serum level of antimüllerian hormone: a randomized controlled trial. Fertil Steril. 2025. PMID: 40403914. doi:10.1016/j.fertnstert.2025.05.151

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。